These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30386824)

  • 41. Radiotherapy versus Surgery in Early-Stage HPV-Positive Oropharyngeal Cancer.
    Kim DY; Wu HG; Kim JH; Lee JH; Ahn SH; Chung EJ; Eom KY; Jung YH; Jeong WJ; Kwon TK; Kim S; Wee CW
    Cancer Res Treat; 2022 Apr; 54(2):406-416. PubMed ID: 34176249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of Human Papilloma Virus status on the prediction of head and neck cancer chemoradiotherapy outcomes using the pre-treatment apparent diffusion coefficient.
    Connor S; Anjari M; Burd C; Guha A; Lei M; Guerrero-Urbano T; Pai I; Bassett P; Goh V
    Br J Radiol; 2022 Feb; 95(1130):20210333. PubMed ID: 34111977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnetic Resonance Imaging-Guided Radiation Therapy for Early-Stage Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
    Dincer N; Ugurluer G; Gungor G; Zoto Mustafayev T; Atalar B; Ozyar E
    Cureus; 2022 Sep; 14(9):e29035. PubMed ID: 36249646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low Tesla magnetic resonance guided radiotherapy for locally advanced cervical cancer: first clinical experience.
    Boldrini L; Piras A; Chiloiro G; Autorino R; Cellini F; Cusumano D; Fionda B; D'Aviero A; Campitelli M; Marazzi F; Balducci M; Valentini V; Gambacorta MA
    Tumori; 2020 Dec; 106(6):497-505. PubMed ID: 32066345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
    J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective
    Mohamed ASR; Bahig H; Aristophanous M; Blanchard P; Kamal M; Ding Y; Cardenas CE; Brock KK; Lai SY; Hutcheson KA; Phan J; Wang J; Ibbott G; Gabr RE; Narayana PA; Garden AS; Rosenthal DI; Gunn GB; Fuller CD;
    Clin Transl Radiat Oncol; 2018 Jun; 11():11-18. PubMed ID: 30014042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
    Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer.
    Lassen P; Primdahl H; Johansen J; Kristensen CA; Andersen E; Andersen LJ; Evensen JF; Eriksen JG; Overgaard J;
    Radiother Oncol; 2014 Dec; 113(3):310-6. PubMed ID: 25544647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy.
    Ihloff AS; Petersen C; Hoffmann M; Knecht R; Tribius S
    Oral Oncol; 2010 Oct; 46(10):705-11. PubMed ID: 20843732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling.
    Ng SP; Bahig H; Wang J; Cardenas CE; Lucci A; Hall CS; Meas S; Sarli VN; Yuan Y; Urbauer DL; Ding Y; Ikner S; Dinh V; Elgohari BA; Johnson JM; Skinner HD; Gunn GB; Garden AS; Phan J; Rosenthal DI; Morrison WH; Frank SJ; Hutcheson KA; Mohamed ASR; Lai SY; Ferrarotto R; MacManus MP; Fuller CD
    BMC Cancer; 2018 Sep; 18(1):903. PubMed ID: 30231854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First experience of autonomous, un-supervised treatment planning integrated in adaptive MR-guided radiotherapy and delivered to a patient with prostate cancer.
    Künzel LA; Nachbar M; Hagmüller M; Gani C; Boeke S; Zips D; Thorwarth D
    Radiother Oncol; 2021 Jun; 159():197-201. PubMed ID: 33812912
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
    Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
    Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.
    Lee N; Schoder H; Beattie B; Lanning R; Riaz N; McBride S; Katabi N; Li D; Yarusi B; Chan S; Mitrani L; Zhang Z; Pfister DG; Sherman E; Baxi S; Boyle J; Morris LG; Ganly I; Wong R; Humm J
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):9-17. PubMed ID: 27511842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls.
    Boldrini L; Cusumano D; Cellini F; Azario L; Mattiucci GC; Valentini V
    Radiat Oncol; 2019 Apr; 14(1):71. PubMed ID: 31036034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer.
    Mehanna H; Gaunt P; Kong A; Hartley A; Sanghera P; Forster M; Sen M; Paleri V; Fong C; Geropantas D; Srinivasan D; Garikipati S; Moleron R; Casswell G; Aynsley E; Ward A; O'Toole L; Mirza A; Firth C; Humphreys I; Fulton-Lieuw T; Roques T; Nankivell P
    Trials; 2024 Jan; 25(1):50. PubMed ID: 38221636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of MR-Guided Radiotherapy for Esophageal Cancer.
    Lee SL; Bassetti M; Meijer GJ; Mook S
    Front Oncol; 2021; 11():628009. PubMed ID: 33828980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy.
    Bohoudi O; Bruynzeel AME; Meijerink MR; Senan S; Slotman BJ; Palacios MA; Lagerwaard FJ
    Radiother Oncol; 2019 Mar; 132():16-22. PubMed ID: 30825964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).
    Regnery S; Ristau J; Weykamp F; Hoegen P; Sprengel SD; Paul KM; Buchele C; Klüter S; Rippke C; Renkamp CK; Pohl M; Meis J; Welzel T; Adeberg S; Koerber SA; Debus J; Hörner-Rieber J
    Radiat Oncol; 2022 May; 17(1):102. PubMed ID: 35614486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.